Amedisys Inc (NASDAQ:AMED) is set to announce its earnings results after the market closes on Wednesday, November 1st. Analysts expect the company to announce earnings of $0.53 per share for the quarter.

Amedisys (NASDAQ:AMED) last issued its earnings results on Wednesday, July 26th. The health services provider reported $0.62 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.50 by $0.12. The firm had revenue of $378.80 million for the quarter, compared to analysts’ expectations of $380.80 million. Amedisys had a net margin of 2.70% and a return on equity of 13.71%. The firm’s revenue was up 5.0% compared to the same quarter last year. During the same quarter last year, the company earned $0.42 earnings per share. On average, analysts expect Amedisys to post $2.21 EPS for the current fiscal year and $2.43 EPS for the next fiscal year.

Shares of Amedisys Inc (NASDAQ:AMED) opened at 49.54 on Wednesday. The company has a 50-day moving average of $51.54 and a 200 day moving average of $55.08. Amedisys Inc has a one year low of $34.58 and a one year high of $65.91. The firm has a market cap of $1.68 billion, a PE ratio of 42.34 and a beta of 0.87.

A number of equities analysts have weighed in on AMED shares. Oppenheimer Holdings, Inc. restated a “buy” rating and issued a $60.00 price target on shares of Amedisys in a report on Friday, September 15th. Jefferies Group LLC restated a “buy” rating and issued a $60.00 price target on shares of Amedisys in a report on Thursday, October 12th. SunTrust Banks, Inc. restated a “buy” rating and issued a $60.00 price target on shares of Amedisys in a report on Monday, October 9th. BidaskClub cut Amedisys from a “strong-buy” rating to a “buy” rating in a report on Wednesday, July 12th. Finally, Royal Bank Of Canada restated a “hold” rating on shares of Amedisys in a report on Monday. Seven equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $56.20.

COPYRIGHT VIOLATION NOTICE: “Amedisys Inc (AMED) Set to Announce Quarterly Earnings on Wednesday” was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another site, it was illegally stolen and reposted in violation of US & international trademark & copyright laws. The original version of this piece of content can be read at https://www.americanbankingnews.com/2017/10/25/amedisys-inc-amed-set-to-announce-quarterly-earnings-on-wednesday.html.

In other Amedisys news, insider David B. Pearce sold 1,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 8th. The stock was sold at an average price of $50.00, for a total value of $50,000.00. Following the transaction, the insider now directly owns 10,488 shares of the company’s stock, valued at approximately $524,400. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Bruce D. Perkins bought 2,000 shares of the business’s stock in a transaction on Thursday, August 3rd. The stock was acquired at an average cost of $46.60 per share, for a total transaction of $93,200.00. Following the completion of the transaction, the director now owns 15,825 shares in the company, valued at $737,445. The disclosure for this purchase can be found here. Corporate insiders own 2.00% of the company’s stock.

Amedisys Company Profile

Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.

Earnings History for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related companies with MarketBeat.com's FREE daily email newsletter.